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Several studies have examined environmental factors and inflammatory bowel diseases (IBD) using 
traditional approaches; however, provided results are still conflicting. Our aim was to determine 
whether lifestyle and nutrient exposures, related to IBD in observational meta‑analyses, influence 
IBD risk using a Mendelian randomization (MR) approach. A two‑sample MR approach was applied on 
summary‑level genome‑wide association results. Genetic variants strongly associated with measures 
of tobacco smoking, obesity and fat distribution, physical activity, and blood levels of vitamins and 
fatty acids were evaluated on genetic data from international IBD consortia including a total of 
25,042 IBD cases (12,194 cases of Crohn’s disease (CD) and 12,366 cases of ulcerative colitis (UC)) and 
34,915 controls. Our results indicated that, among lifestyle exposures, being a smoker was positively 
associated with CD (OR 1.13, P = 0.02), but it was not associated with UC risk (OR 0.99, P = 0.88). Body‑
mass index (BMI) and body fat percentage were positively associated with CD (OR 1.11, P = 0.02, per 
standard deviation (SD) of 4.6 kg/m2; and OR 1.50, P = 3 × 10–10, per SD of 6.6%; respectively); while 
for UC, BMI was inversely associated (OR 0.85, P = 5 × 10–5; per SD) and body fat percentage showed 
a OR of 1.11 (P = 0.11; per SD). Additionally, among nutrient exposures, omega‑3 fatty acids levels 
were inversely associated with CD (OR 0.67, P = 2 × 10–6). Our MR results did not support a protective 
effect for being a smoker on UC risk; however, they are compatible with a risk effect for higher body fat 
proportion and a protective role for higher levels of omega‑3 fatty acids on CD etiology.
Inflammatory bowel diseases (IBD) become chronic disorders as consequence of dysregulated immune response 
to intestinal dysbiosis in genetically susceptible individuals, with fluctuating periods between remission and 
 relapses1. There exist two main types of IBD, namely Crohn’s disease (CD) and ulcerative colitis (UC). They differ, 
among other features, on the location of the affected mucosa; CD can affect discontinuously different regions of 
the gastrointestinal tract, typically ileum and colon, while UC starts in the rectum and may involve proximally 
the colon in a continuous  fashion2,3.
IBD incidence and prevalence have stabilized in most economically developed areas, but continue to rise 
in areas in transition towards developed  economies4. This links the IBD main risk factors to westernization 
of lifestyle. External environmental factors can contribute to gut dysbiosis, reducing microbiome diversity or 
introducing non-commensal microorganism, alter the integrity of the epithelial barrier, and trigger an altered 
immune  response5. Environmental risk factors for gut dysbiosis and IBD are lifestyle parameters such as cigarette 
smoking, obesity, physical inactivity, and a western-type of diet (characterized by high intake of saturated fat, 
refined carbohydrates, red and processed meat, and low intake of fruits, vegetables, fiber, and fish)6,7. A recent 
umbrella review of meta-analyses identified risk and protective factors with different levels of strength of epi-
demiologic evidence; however, subgroup analyses showed differential associations for factors such as smoking 
and folate  levels7.
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Novel analytical methodologies aim to provide evidence of causality using genetic proxies for putative risk 
factors in instrumental variable analyses. Recently, one of these methods, called Mendelian randomization (MR), 
has become popular as large-scale genome-wide association studies (GWAS) allow the identification of genetic 
variants reliably associated with putative risk  factors8. This methodology was proposed as analogous approach to 
a classical randomized controlled trial (RCT), the gold standard to establish causality. The random segregation 
of alleles at conception provides naturally two groups of population differentiated exclusively by the genetics 
of the putative risk factors (Fig. 1), mimicking the effect of the treatment and control arms in a RCT. Under the 
methodological assumptions, this approach avoids biasing effects from reverse causation (as disease onset does 
not affect germ-line genetics), and it is largely free from confounding (as the genetic basis of different risk fac-
tors are independent)9. The results from a MR approach allow a better estimation of the risk contribution of a 
putative risk factor, and support the development of preventive disease strategies.
In this study, for those environmental risk factors previously identified in large meta-analyses and with avail-
able GWAS data, we aimed to provide further evidence of potential causation using a two-sample MR approach. 
We reviewed and identified genome-wide variants associated with putative risk factors, and tested them on GWAS 
data from large-scale IBD international consortia comprising more than 50,000 individuals.
Materials and methods
This study was based on summary-level genome-wide association results under a two-sample MR  approach10. 
Initially, genetic variants strongly associated with each exposure were identified as instruments in large-scale 
GWAS results (first sample). Subsequently, for the identified instruments, association data on IBD and subtypes 
were retrieved from IBD international consortia results (second sample). Genetics-to-exposure results were 
combined with genetics-to-IBD results to obtain exposure-to-IBD effect estimates through a likelihood-based 
MR approach. The consistency of initial results was evaluated by applying several complementary MR analyses.
Identification of genetic determinants for potential risk factors. Analyzed factors included meas-
ures of tobacco smoking, obesity and fat distribution, overall physical activity, and blood metabolite levels 
affected by a western-type of diet, such as vitamins and fatty acids.
Initially, genome-wide associated single nucleotide polymorphisms (SNPs) (P < 5 × 10–8) were identified as 
genetic instruments in European-based studies. Recently published GWAS using or including the European 
individuals from the UK Biobank cohort are a rich source of genetic instruments. UK Biobank is a prospective 
cohort that recruited more than 500,000 men and women aged 40–96 years between 2006 and 2010, and collected 
anthropometric, health and lifestyle  data11. The genetic etiology of tobacco smoking was recently described in a 
 GWAS12 comprising up to 1.2 million individuals from the Tobacco and Genetics (TAG) consortium, 23andMe 
database, and the UK Biobank cohort. From this study we identified genetic instruments for risk of ever being 
smoker (ever vs never smokers), and number of cigarettes smoked per day. Regarding obesity and fat distribution 
measures, genetic instruments for body-mass index (BMI)13 and waist-to-hip  ratio14 were retrieved from meta-
analyses combining GWAS results from the Genetic Investigation of ANthropometric Traits (GIANT) consortium 
and the UK Biobank cohort comprising nearly 700,000 individuals. Genome-wide associated SNPs for body fat 
Figure 1.  Mendelian randomization as an analogous approach to a classical randomized control trial (RCT).
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percentage (total fat mass/ total mass)15 were identified from GWAS using nearly 360,000 UK Biobank indi-
viduals. Likewise, physical activity was recently genetically assessed in the UK Biobank cohort. Overall physical 
activity was measured using a wrist-worn accelerometer device in a subsample of 91,000  individuals16. Finally, we 
analyzed vitamins and fatty acids levels as metabolites affected by the type of dietary  intake17,18. Genetic instru-
ments were identified for circulating levels of vitamin  D19, vitamin B9 and  B1220, polyunsaturated omega-3 and 
omega-6, monounsaturated (mainly omega-7 and omega-9) fatty acids, and total fatty  acids21.
From the initial sets of SNPs, we selected uncorrelated SNPs based on linkage disequilibrium (LD)  R2 < 0.01. 
SNPs with ambiguous strand codification (A/T or C/G) were replaced by SNPs in genetic linkage  (R2 > 0.8) using 
the proxysnps R package (European populations) (R Project). SNP-to-exposure association summary statistics 
were retrieved from the original GWAS studies, and can be observed in Supplementary Table S1 online. In the 
studies where summary statistics were not reported in standard deviations (SD), they were transformed based 
on SD reported in the original GWAS studies. Table 1 describes genetic instruments features on the number of 
SNPs included, the proportion of phenotype variance explained by the SNPs (or cumulative SNP liability in the 
case of binary outcomes), as well as the mean and SD of the respective exposure in the original GWAS studies.
GWAS data on inflammatory bowel diseases and subtypes. The largest GWAS on IBD and sub-
types was based on meta-analyses results of European samples from the International IBD Genetics Consortium 
and the UK IBD Genetics  Consortium22. This study comprised a total of 25,042 cases of IBD, including 12,194 
cases of CD and 12,366 cases of UC, and 34,915 controls. SNP-to-IBD and subtypes association summary statis-
tics for the selected SNPs were retrieved from this GWAS study, and can be observed in Supplementary Table S1 
online.
Statistical analyses. Following the method proposed by  Burgess23, a priori power calculations were per-
formed for MR associations of nominal statistical significance (α < 0.05). Power estimates depend on the phe-
notype variance explained by the genetic instrument, outcome sample size and case/control ratio. Minimum 
detectable odds ratios (OR) by the given genetic instruments and IBD samples can be observed in Table 1. In 
brief, most of the tested measures, 10 out of 13, showed enough power to detect moderate risk increases of 20% 
(minimum detectable OR < 1.20) (Table 1). The analyses with less power were for overall physical activity, which 
genetic instrument explained 0.08% of phenotype variance, with a minimum detectable OR of 2.27 for IBD risk.
Estimated effects of each exposure on IBD, CD and UC outcomes reflected by each genetic variant (Wald 
estimates: βoutcome/βexposure) were combined in a single estimate per outcome through a likelihood-based MR 
 approach10. This method assumes a linear relationship between the risk factor and outcome and a bivariate 
normal distribution for the genetic association estimates. Bonferroni multiple test correction was applied to 
consider evidence of exposure-to-IBD association (significance = 0.05/13: 0.0038). Heterogeneity between CD 
and UC risk effects was evaluated estimating the P value  (Pdisease het) for the Q statistic for heterogeneity, assuming 
a fixed-effect model of 1 degree of freedom. This MR approach is considered the most accurate method when 
the assumption of linear relationship between the exposure and the outcome (common assumption for the other 
Table 1.  Description of genetic instruments for observed environmental risk factors. nSNP number of single 
nucleotide polymorphisms, SD standard deviation, Var: explained phenotype variance, Pub ref discovery 
GWAS, OR odds ratio; IBD Inflammatory bowel disease; CD Crohn’s disease; UC ulcerative colitis. *Range 
(minimum–maximum).





Smoking status 331 - - Ever/never 2.3 12 1.17 1.22 1.21
Cigarettes per day 44 2.35 0.94 n cigarettes 1.1 12 1.25 1.34 1.32
Body-mass index 816 26.97 4.65 Kg/m2 6.0 13 1.10 1.13 1.13
Waist-to-hip ratio 403 1 0.1 – 3.0 14 1.14 1.19 1.19
Body fat percentage (fat/total 
mass) 378 31.8 6.6 % 3.5
15 1.13 1.18 1.17
Overall physical activity 2 27.89 8.14 Mili-gravities (acceleration) 0.08 16 2.27 2.93 2.83
Nutrients
Vitamin D 59 70.0 34.7 nmol/l 3.4 19 1.13 1.18 1.17
Vitamin B9 (folate) 2 13.4 8.44 nmol/l 1.0 20 1.26 1.36 1.34
Vitamin B12 10 342.68 150.11 pmol/L 6.3 20 1.10 1.13 1.12
Omega-3 fatty acids 4 0.41 0.08–1.80* mmol/l 2.4 21 1.16 1.22 1.21
Omega-6 fatty acids 8 4 1.8–12.0* mmol/l 4.6 21 1.11 1.15 1.15
Monounsaturated fatty 
acids (mainly omega-9 and 
omega-7)
4 3.3 1.1–15.0* mmol/l 2.4 21 1.16 1.22 1.21
Total fatty acids 8 11.7 4.6–42.0* mmol/l 3.7 21 1.13 1.17 1.17
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methods as well) is  held24. However, it is sensitive to invalid instruments due to pleiotropic SNP effects (i.e. SNP 
effects on the outcome independent from the proxied exposure: horizontal pleiotropy).
Several complementary MR approaches were applied to detect the presence of horizontal pleiotropy, outliers 
(SNPs with strong pleiotropy), and unbalanced horizontal pleiotropy of weak instruments. The initial sensitivity 
test is called MR pleiotropy residual sum and outlier (MR-PRESSO)  test25. This method identifies heterogeneity 
between SNP effects  (PGlobal) as evidence of horizontal pleiotropy. Subsequently, it identifies outlier SNPs and 
provides evidence of biased effect on the initial risk estimates  (PDistortion). Another complementary MR method 
is called MR-Egger  test26. This method identifies the presence of non-balanced horizontal pleiotropy in weak 
instruments (i.e. SNP effects biased towards one direction) in the intercept test of the regression analyses between 
SNP-to-exposure effects and SNP-to-outcome effects. The violation of this assumption (non-balanced pleiotropy) 
is critical for all other MR methods. Finally, to test the consistency of the initial risk estimates, two methods that 
rely on the density distribution of individual SNP exposure-to-outcome effects were applied, namely weighted 
median MR  method27 and the modal-based MR estimate  approach28. These methods estimate the weighed 
median and the mode, respectively, of this density distribution, and are less sensitive to the presence of invalid 
SNPs (SNPs with mild pleiotropic effect).
To visualize the SNP exposure-to-outcome effects and the presence of pleiotropic SNPs, scatter plots were 
used to depict the SNP-to-exposure and SNP-to-IBD effects, including the likelihood-based MR risk estimate. 
Statistical analyses were performed using R (The R project; R version 3.4.1), the TwoSampleMR (version 0.4.18) 
and MRPRESSO (version 1.0) R packages, and plots were generated using ggplot2 R package (version 3.1.0).
Results
Lifestyle exposures. Tobacco smoking was not robustly related to IBD risk. Initially, the genetic instru-
ment for risk of ever being smoker was associated with a mild 13% risk increase for CD (95% confidence interval 
(95% CI) 1.02–1.25); while it was not for UC risk (OR 0.99, 95% CI 0.90–1.10)  (Pdisease het = 0.08) (Fig. 2). Smok-
ing intensity (number of cigarettes smoked per day) showed OR of 1.17 (95% CI 0.94–1.44, per SD of 1.1 extra 
cigarettes) and 0.90 (95% CI 0.73–1.10, per SD) for CD and UC, respectively (Fig. 2). In the sensitivity analyses, 
MR-PRESSO test detected horizontal pleiotropy  (PGlobal < 8.7 × 10–3) and potential outlier SNPs; however, the 
presence of outlier SNPs did not bias the initial risk estimates  (PDistortion > 0.19). MR Egger test detected evidence 
of directional pleiotropy for smoking intensity and CD risk  (PEgger intercept = 4 × 10–3), and provided an OR of 0.73 
(95% CI 0.41–1.28, per SD). The other MR sensitivity approaches provided association estimates around the null 
for smoking status and smoking intensity on CD and UC risk (Supplementary Table S2 online). The scatter plots 
for the MR smoking status-to-CD association and smoking status-to-UC association are included in Fig. 3, while 
the other scatter plots can be observed in Supplementary Fig. S1 online.
We initially estimated that each SD increase in body-mass index (BMI; 4.6 kg/m2) and waist-to-hip ratio (0.1) 
were positively associated with CD risk (OR 1.11, 95% CI 1.02–1.20; and OR 1.22, 95% CI 1.09–1.37; respec-
tively), but were inversely associated with UC risk (OR 0.85, 95% CI 0.78–0.92; and OR 0.90, 95% CI 0.81–1.01; 
respectively)  (Pdisease het < 2.1 × 10–4) (Fig. 2). On the contrary, each SD increase in body fat percentage (6.6%) 
was positively associated with CD risk (OR 1.50, 95% CI 1.32–1.71) and UC risk (OR 1.11, 95% CI 0.98–1.25) 
 (Pdisease het = 7.3 × 10–4) (Fig. 2). Horizontal pleiotropy and potential outliers were observed in all the cases, however 
without biasing the observed risk estimates  (PGlobal < 1 × 10–4,  PDistortion > 0.08) (Supplementary Table S2 online). 
Directional pleiotropy was not observed  (PEgger intercept > 0.02), and the other MR sensitivity approaches provided 
similar relative risk estimates (Supplementary Table S2 online). The scatter plots depicting the MR BMI-to-UC 
association and body fat percentage-to-CD association are included in Fig. 4. The other scatter plots can be 
observed in Supplementary Fig. S1 online.
Overall physical activity showed an inverse association with IBD risk (OR 0.51, 95% CI 0.27–0.98, per SD of 
8.1 miligravities of acceleration), without heterogeneity between CD and UC  (Pdisease het = 0.51) (Fig. 2). However, 
SNP heterogeneity was observed for CD (P = 1.5 × 10–3), which was significant for a 2-SNP genetic instrument 
(Supplementary Table S2 online).
Nutrient exposures. One SD increase in circulating vitamin D levels (34.7 nmol/l) showed null association 
with IBD risk (OR 0.96, 95% CI 0.87–1.06), without heterogeneity between CD and UC  (Pdisease het = 0.85) (Fig. 5). 
Horizontal pleiotropy and potential outliers were observed, however without biasing the observed risk estimates 
 (PGlobal < 1 × 10–4,  PDistortion > 0.77) (Supplementary Table S2 online). MR vitamin D-to-IBD scatter plot can be 
observed in Fig. 6a. Regarding B vitamins, one SD increase in circulating vitamin B9 levels (8.44 nmol/l) showed 
an OR of 0.83 (95% CI 0.67–1.03) for IBD  (Pdisease het = 0.59) (Fig. 5); however, SNP heterogeneity was observed 
for the 2-SNP instrument (P = 2.5 × 10–3; Supplementary Table S2 online). One SD increase in vitamin B12 levels 
(150.11 pmol/L) was initially associated with CD (OR 1.10, 95% CI 1.00–1.21) and UC (OR 1.06, 95% CI 0.97–
1.15)  (Pdisease het = 0.52) (Fig. 5). However, MR-PRESSO test detected horizontal pleiotropy  (PGlobal < 1 × 10–4) and 
an outlier SNPs slightly biasing the initial risk estimate for CD  (PDistortion = 0.02), while the other sensitivity MR 
analyses provided null estimates for the vitamin B12-to-IBD and subtypes associations (OR from 0.92 to 1.09) 
(Supplementary Table S2 online). Scatter plots can be observed in Supplementary Fig. S1 online.
Finally, we observed that omega-3 fatty acid levels were inversely associated with IBD (OR 0.78, 95% CI 
0.68–0.88, per SD of ~ 0.20 mmol/l). Some heterogeneity was observed between CD and UC  (Pdisease het = 0.02), 
with ORs of 0.67 (95% CI 0.56–0.79) and 0.88 (95% CI 0.75–1.03), respectively (Fig. 5). The other analyzed 
fatty acid measures did not show association with IBD (OR 0.96, 95% CI 0.88–1.05, for omega-6 fatty acids; OR 
0.94, 95% CI 0.82–1.08, for monounsaturated fatty acids (mainly omega-7 and omega-9); and OR 0.94, 95% CI 
0.85–1.04, for total fatty acids) (Fig. 5). Neither outlier SNPs, nor horizontal or directional pleiotropic effects 
were observed in these analyses. Additionally, the other MR methods provide similar relative risk estimates 
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(Supplementary Table S2 online). The scatter plot for the MR omega-3 fatty acids-to-CD relationship is included 
in Fig. 6b, while the other scatter plots can be observed in Supplementary Fig. S1 online.
Discussion
In this Mendelian randomization study, we found no evidence for a robust role of smoking on IBD and subtypes 
etiology. On the contrary, our results support an increased risk for higher body fat proportion and a protective 
role for higher levels of omega-3 fatty acids on CD etiology, as observed in large meta-analyses.
The most consistently reported potential risk factor for CD is tobacco smoking, showing risk increases higher 
than 50%. On the contrary, the role of smoking on UC has been observed as protective with similar  strength7. 
Our MR study is powered enough to validate the described associations, but we only observed a potential relative 
risk increase of 13% for ever being smoker on CD risk; with inconclusive results in the MR sensitivity analyses. 
Therefore, the observed associations in traditional meta-analyses could be confounded by other factors associ-
ated with both smoking and IBD subtypes. Supporting this evidence, there are some studies describing a null 
association with other types of nicotine consumption (moist snuff)29 or in non-European  populations30.
There is considerable evidence that links obesity and IBD risk; a considerable proportion of IBD patients are 
obese, the incidence of both obesity and IBD is increasing, and obesity strongly modifies gut  microbiota31,32. 
Despite this, findings from cross-sectional and cohort studies are conflicting; cross-sectional studies showed 
Figure 2.  Forest plot of IBD risk for increment in lifestyle exposures. OR per standard deviation increase were 
estimated using likelihood-based MR approach. 95% CI 95% confidence interval; P P value. Pdisease het P value of 
heterogeneity between Crohn’s disease (CD) and ulcerative colitis (UC).
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an inverse association between BMI and IBD and  subtypes7, while cohort and population-based studies have 
described a positive association between BMI and CD, but a negative trend between BMI and  UC31,33. The pre-
sent MR study is supporting the observations from cohort-based studies, and reveals a potential effect of reverse 
causation in the results from cross-sectional studies. Additionally, this opposing effect of BMI on CD and UC is 
similar to the reported pattern between being smoker and IBD subtypes in observational studies. Recently, a MR 
study analyzing obesity measures and smoking habits in more than 300,000 individuals identified higher levels 
of obesity as a factor increasing the risk for ever being a smoker and smoking at higher  intensity34. Therefore, we 
hypothesize that the traditionally observed relation between smoking and IBD subtypes could be confounded 
by obesity, specially BMI. Finally, our MR results also confirmed that fat proportion would be more predictive 
for developing IBD, specially CD, than general obesity  measures31.
Figure 3.  Scatter plots depicting summary statistics for genetic association and likelihood-based MR results of 
smoking status on CD (a), and smoking status on UC (b).
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Physical activity showed a robust inverse association with IBD and subtypes in large meta-analyses7. One 
limitation of the present MR study is the low statistical power for the overall physical activity genetic instrument 
(2 SNPs explaining the 0.08% of phenotype variance). Despite this, our MR estimate would be compatible with 
a protective effect of physical activity on IDB and subtypes risk.
Westernization of diet, characterized by high levels of saturated fat, red and processed meat instead of fish, and 
vitamin deficiency, is thought to be partially behind the rise in IBD  incidence35. Both higher levels of D and B9 
vitamins have been observed to reduce the IBD risk by 30% or more in large meta-analyses7,36. In a previous MR 
study on vitamin D, an association with IBD risk was not found; however this study included approximately 2,000 
IBD  cases37. Our well-powered MR study, including 25,042 IBD cases, would not be consistent with a protective 
effect for higher levels of vitamin D and folate on IBD and subtypes risk. Regarding fatty acids, omega-3 fatty 
acids have been associated with a reduced risk, while omega-6 fatty acids are considered a risk factor; however, 
Figure 4.  Scatter plots depicting summary statistics for genetic association and likelihood-based MR results of 
body-mass index on UC (a), and body fat percentage on CD (b).
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there is no clear evidence of omega-3 therapeutic  efficacy38–41. Our MR study provided evidence for a reduction 
of CD risk with higher levels of omega-3 fatty acids. The contribution of omega-3 reducing the CD risk would 
be mediated by their contribution to provide pro-resolving molecules in inflammatory  processes41.
Despite limitations already mention, the main limitation of this study is the lack of analyses for putative risk 
factors related with living spaces, pre and post-natal, and birth conditions, surgeries, drugs, and microbiota risk 
factors, also observed in large meta-analyses7. For most of those factors, genetic instruments were not available 
because of the lack of genetic predisposition for those exposures. Recently, it has been assessed under a MR 
approach the contribution of microbial related traits (fecal propionate levels and butyrate gut production) on 
several metabolic  parameters42. These genetic instruments did not reach our selection parameters, and we con-
sidered them unreliable. Studies with larger sample sizes are needed to identify microbial genetic instruments. 
Figure 5.  Forest plot of IBD risk for increment in nutrient exposures. OR per standard deviation increase were 
estimated using likelihood-based MR approach. 95% CI: 95% Confidence Interval; P: P value.  Pdisease het: P value 
of heterogeneity between Crohn’s disease (CD) and ulcerative colitis (UC).
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Finally, another limitation of this MR study is the potential violation of MR assumptions regarding pleiotropic 
effects on the analyzed genetic instruments; however, MR sensitivity analyses and graphical scatter plots were 
used to avoid biases of this nature.
In conclusion, our MR results did not support a robust role of smoking on IBD and subtypes etiology; how-
ever, they were compatible with a risk effect for higher body fat proportion and a protective effect for higher levels 
of omega-3 fatty acids on CD etiology, observed in meta-analyses. These results provided a better estimation of 
the contribution of risk factors to IBD etiology, and supported the development of preventive disease strategies 
related to physical activity and diet.
Figure 6.  Scatter plots depicting summary statistics for genetic association and likelihood-based MR results of 
vitamin D on IBD (a), and omega-3 fatty acids on CD (b).
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Data availability
The dataset needed to reproduce the results is found in the Supplementary Table S1 online. URL for GWAS on 
IBD and subtypes: ftp://ftp.sange r.ac.uk/pub/proje ct/humge n/summa ry_stati stics /human /2016-11-07/.
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